ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

WHO panel strongly advises against hydroxychloroquine for COVID

Experts say further research into Trump-fanned issue is 'not worthwhile'

The anti-inflammatory drug should not be used to fight the pandemic, the WHO's Guideline Development Group writes in a British medical journal.   © Reuters

The drug hydroxychloroquine, once touted by Donald Trump as a pandemic "game-changer," should not be used to prevent COVID-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said on Tuesday.

The anti-inflammatory drug should not be used in the fight against the pandemic, the WHO's Guideline Development Group (GDG) expert panel wrote in the BMJ British medical journal, and is "not worthwhile" exploring in further research studies of possible COVID-19 treatments.

This "strong recommendation", the experts said, is based on high-certainty evidence from six randomized controlled trials involving more than 6,000 participants both with and without known exposure to COVID-19.

Former U.S. President Trump said last March that hydroxychloroquine could be a game-changer in the coronavirus pandemic. He also said he was taking it himself, even after the U.S. medicines regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.

But the WHO's experts said they now "judged that almost all people would not consider this drug worthwhile".

"The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent COVID-19," they wrote.

The WHO noted in a statement that the recommendation is a so-called "living guideline" on potential drugs for COVID-19.

The guidelines, which can be updated as new evidence emerges, are designed to advise doctors and health care providers on managing the respiratory disease and help them make better decisions for patients.


Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more